PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16795009

Understanding processing-induced phase transformations in erythromycin-PEG 6000 solid dispersions.

Sabiruddin Mirza·Jyrki Heinämäki·Inna Miroshnyk·Jukka Rantanen·Leena Christiansen·Milja Karjalainen·Jouko Yliruusi
View original source ↗Export metadata ↓

Abstract

Since the quality and performance of a pharmaceutical solid formulation depend on solid state of the drug and excipients, a thorough investigation of potential processing-induced transformations (PITs) of the ingredients is required. In this study, the physical phenomena taking place during formulation of erythromycin (EM) dihydrate solid dispersions with polyethylene glycol (PEG) 6000 by melting were investigated. PITs were monitored in situ using variable temperature X-ray powder diffraction (VT-XRPD), differential scanning calorimetry (DSC), and hot-stage microscopy (HSM). Possible intermolecular interactions between the drug and polymer in the solid state were further studied by Fourier transform infrared (FTIR) spectroscopy. While in the absence of PEG the dehydration was the only transformation observed, hot-melt processing with the polymer caused the drug to undergo multiple phase transformations (EM dihydrate --> EM dehydrate --> EM anhydrate). This alteration in phase behavior of EM was attributed to the ability of PEG in promoting nucleation and crystal growth of the EM anhydrate through a solvent-mediated route. In situ monitoring of solid dispersion formation, especially by VT-XRPD and HSM, enabled both early-stage detection of phase transformations during the hot-melt processing and better process understanding.

Explore related subjects

Chemistry, PharmaceuticalErythromycinPolyethylene GlycolsSpectroscopy, Fourier Transform InfraredX-Ray DiffractionJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sabiruddin Mirza, Jyrki Heinämäki, Inna Miroshnyk, Jukka Rantanen, Leena Christiansen, Milja Karjalainen, Jouko Yliruusi. 2006. Understanding processing-induced phase transformations in erythromycin-PEG 6000 solid dispersions.. https://doi.org/10.1002/jps.20640

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts.

The introduction of HIV-1 protease (HIV-PR) inhibitors has led to a dramatic increase in patient survival; however, these gains are threatened by the emergence of multi-drug-resistant strains. Design of inhibitors that overcome resistance would be greatly facilitated by deeper insight into the mechanistic events associated with binding of substrates and inhibitors, as well as an understanding of the effects of resistance mutations on the structure and dynamic behavior of HIV-PR. We previously reported a series of simulations that provide a model for HIV-PR dynamics, with spontaneous conversions between the bound and unbound crystal forms upon addition or removal of an inhibitor. Importantly, the unbound protease transiently sampled a third fully open state that permits entry to the active site, unlike both crystallographic forms. Recently, a crystal structure of unbound HIV-PR was reported for the MDR 769 isolate (PDB: 1TW7); unlike all previous experimental structures, the binding pocket is open. It is suggested that drug resistance in this strain arises at least in part from the inability of inhibitors to induce closing. We carried out simulations of the MDR 769 HIV-PR mutant and observed that the reported structure is unstable in solution and rapidly adopts the semi-open conformation observed for the unbound wild-type protease in solution. Further analysis suggests that the wide-open structure observed for MDR 769 arises not from sequence variation, but instead is an artifact from crystal packing. Thus, despite being the first experimental structure to reveal flap opening sufficient for substrate access to the active site, this structure may not be directly relevant to studies of inhibitor entry or to the cause of HIV-PR drug resistance.

Chemistry, Pharmaceutical↗
PubMed2006

Leadlikeness and structural diversity of synthetic screening libraries.

High program failure rates in the pharmaceutical industry have prompted the development of predictive software that can profile compound libraries as being 'druglike' (resembling existing drugs) and/or 'leadlike' (possessing the structural and physicochemical profile of a quality lead). In recent years, these two notions prompted pharmaceutical companies to clean up their corporate libraries of screening compounds. In order to maintain and expand the size and diversity of these corporate libraries, pharmaceutical companies still continue to add compounds to these, mainly by the acquisition of screening libraries. In this paper, we have analyzed 45 commercially available libraries, offered by suppliers of screening chemistry, for leadlikeness and diversity of the offered structures. To this end we have used a set of structural and physicochemical filters for leadlikeness that was developed in-house. These 45 supplier libraries contained a total of 5.3 million structures, of which 49% (2,592,778 structures) turned out to be unique, and only 12% (677,328 structures) were found to be both unique and leadlike. A diversity analysis revealed that big differences exist between the various offered libraries.

Chemistry, Pharmaceutical↗
PubMed2006

JEDA: Joint entropy diversity analysis. An information-theoretic method for choosing diverse and representative subsets from combinatorial libraries.

The joint entropy-based diversity analysis (JEDA) program is a new method of selecting representative subsets of compounds from combinatorial libraries. Similar to other cell-based diversity analyses, a set of chemical descriptors is used to partition the chemical space of a library of compounds; however, unlike other metrics for choosing a compound from each partition, a Shannon-entropy based scoring function implemented in a probabilistic search algorithm determines a representative subset of compounds. This approach enables the selection of compounds that are not only diverse but that also represent the densities of chemical space occupied by the original chemical library. Additionally, JEDA permits the user to define the size of the subset that the chemist wishes to create so that restrictions on time and chemical reagents can be considered. Subsets created from a chemical library by JEDA are compared to subsets obtained using other partition-based diversity analyses, namely principal components analysis and median partitioning, on a combinatorial library derived from the Comprehensive Medical Chemistry Dataset.

Chemistry, Pharmaceutical↗